Cara Therapeutics Files 8-K on Financials
Ticker: TVRD · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Cara Therapeutics, Inc. (TVRD) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: CARA
TL;DR
Cara Therapeutics dropped an 8-K on March 4th detailing their financials. Check it out.
AI Summary
Cara Therapeutics, Inc. filed an 8-K on March 4, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Stamford, Connecticut.
Why It Matters
This filing provides an update on Cara Therapeutics' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- Cara Therapeutics, Inc. (company) — Filer of the 8-K
- March 4, 2024 (date) — Date of report
- Stamford, Connecticut (location) — Location of principal executive offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filed?
The 8-K was filed on March 4, 2024.
Where is Cara Therapeutics, Inc. headquartered?
The company's principal executive offices are located at 400 Atlantic Street, Suite 500, Stamford, Connecticut.
What is Cara Therapeutics' fiscal year end?
The fiscal year end for Cara Therapeutics is December 31st.
What is the SEC file number for Cara Therapeutics?
The SEC file number for Cara Therapeutics is 001-36279.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-04 16:10:56
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Marke
Filing Documents
- tm247839d1_8k.htm (8-K) — 25KB
- tm247839d1_ex99-1.htm (EX-99.1) — 97KB
- tm247839d1_ex99-1img01.jpg (GRAPHIC) — 5KB
- 0001104659-24-030494.txt ( ) — 311KB
- cara-20240304.xsd (EX-101.SCH) — 3KB
- cara-20240304_lab.xml (EX-101.LAB) — 33KB
- cara-20240304_pre.xml (EX-101.PRE) — 22KB
- tm247839d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On March 4, 2024, Cara Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 4, 2024 104 Cover page interactive data file (formatted as Inline XBRL) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARA THERAPEUTICS, INC. By: /s/ RYAN MAYNARD Ryan Maynard Chief Financial Officer (Principal Financial and Accounting Officer) Date: March 4, 2024 3